EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal

Ram Kumar Mahato iD, Gokarna Dahal, Yadu Chandra Ghimire, Rudra Prasad Marasini, David T S Hayman iD, Kaliannagounder Krishnamoorthy iD, Sunil Raj Sharma, Dipak Sah, Ram Balak Ray, Radha Subedi, Keshav Raj Pandit, Sudip Raj Khatiwada und 13 weitere

PLOS Global Public Health · 24.04.2026 · 6 (4) · e0004809

DOI: 10.1371/journal.pgph.0004809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 24.04.2026. Verfasst von Ram Kumar Mahato und 24 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Disease Control Division, Teku, Kathmandu, Nepal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RTI International.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nepal aims to eliminate lymphatic filariasis (LF) by 2030. Mass drug administration (MDA) has ceased in 53 of the 64 endemic districts. Following failure to pass the pre-Transmission Assessment Survey of antigenemia prevalence, five districts completed two rounds of MDA using a three-drug regimen (Ivermectin, Diethylcarbamazine, and Albendazole; IDA) and achieved over 65% coverage of the total population in 2023 and 2024. An Epidemiological Monitoring Survey (EMS) was conducted to evaluate IDA’s impact. A cross-sectional EMS was conducted 9 months post-MDA in 11 evaluation units (EUs) across five districts, using two sites per EU (n = 22). A total of 6,829 individuals aged ≥20 years were sampled via multi-stage methods, with ≥300 blood samples per site. Data on demographics and MDA participation were collected. LF antigen testing was followed by night blood microfilariae testing in antigen-positive samples. Analysis included non-parametric tests, logistic and mixed-effects models accounting for site-level clustering, and penalized regression (lasso and ridge) to assess predictor importance and manage multicollinearity. Nine of 11 EUs passed EMS. Two EUs in Kapilvastu failed due to ≥1% microfilariae prevalence in at least one site. Microfilariae prevalence was negatively correlated with site MDA coverage (p-value 0.04), but not antigen prevalence (p-value 0.8). Overall, 4.63% of participants were antigen-positive and 0.34% were microfilariae-positive (ratio 14:1). Being female (OR 0.12; 95% CI: 0.04–0.36) and participation in latest MDA round (OR 0.34; 95% CI: 0.15–0.77) were associated with lower microfilariae prevalence. Suboptimal impact of MDA was observed in two EUs based on microfilariae prevalence and may reflect insufficient treatment compliance. Two additional rounds of MDA with directly observed treatment are recommended to improve adherence. Female sex and participation in the most recent MDA round were associated with reduced odds of microfilaremia. Targeted strategies focusing on men and other identified risk groups may enhance program effectiveness.

Autor:innen und Institutionen

  • Epidemiology and Disease Control Division, Teku, Kathmandu, Nepal.
  • Molecular Epidemiology and Public Health Laboratory, Infectious Disease Research Centre, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand.
  • ICMR-Vector Control Research Centre, Puducherry, India.
  • Vector Borne Disease Research and Training Center, Hetauda, Makwanpur, Nepal.
  • RTI International, Act to End NTDs | East, Kathmandu, Nepal.
  • RTI International, Act to End NTDs | East, Research Triangle Park, North Carolina, United States of America.

ORCID-Profile: Ram Kumar Mahato, David T S Hayman, Kaliannagounder Krishnamoorthy, Briana Stone, Ashna Parajuli, Satya Raj Paudel, Bhim Prakash Devkota, Bhim Prasad Sapkota, Bijay Bajracharya

Förderung

  • RTI International

Zitieren

APA

Mahato, R. K., Dahal, G., Ghimire, Y. C., Marasini, R. P., Hayman, D. T. S., Krishnamoorthy, K., Sharma, S. R., Sah, D., Ray, R. B., Subedi, R., Pandit, K. R., Khatiwada, S. R., Ojha, A. B., Mahaseth, S., Mahata, D. B., Brady, M., Burgert-Brucker, C. R., Stone, B., Parajuli, A., …, & Bajracharya, B. (2026). Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal. PLOS Global Public Health, 6(4), e0004809. https://doi.org/10.1371/journal.pgph.0004809

Vancouver

Mahato RK, Dahal G, Ghimire YC, Marasini RP, Hayman DTS, Krishnamoorthy K, et al. Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal. PLOS Global Public Health. 2026;6(4):e0004809. doi:10.1371/journal.pgph.0004809

BibTeX
@article{Mahato2026,
  author = {Mahato, Ram Kumar and Dahal, Gokarna and Ghimire, Yadu Chandra and Marasini, Rudra Prasad and Hayman, David T S and Krishnamoorthy, Kaliannagounder and Sharma, Sunil Raj and Sah, Dipak and Ray, Ram Balak and Subedi, Radha and Pandit, Keshav Raj and Khatiwada, Sudip Raj and Ojha, Achut Babu and Mahaseth, Saroj and Mahata, Deepak Bahadur and Brady, Molly and Burgert-Brucker, Clara R and Stone, Briana and Parajuli, Ashna and Paudel, Satya Raj and Devkota, Bhim Prakash and Jha, Chandra Bhal and Paudel, Krishna Prasad and Sapkota, Bhim Prasad and Bajracharya, Bijay},
  title = {Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal},
  journal = {PLOS Global Public Health},
  year = {2026},
  volume = {6},
  number = {4},
  pages = {e0004809},
  doi = {10.1371/journal.pgph.0004809}
}
Kostenlos starten →